Clinical Trial Update: Rosuvastatin to Decrease Residual Immune Activation in HIV Infection [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating whether rosuvastatin can reduce residual immune activation in HIV infection.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Rosuvastatin (rosuvastatin)

Snippet

Sponsor: Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba | Conditions: HIV-1 Infection | Phase 2 | Status: UNKNOWN